Professional Documents
Culture Documents
In this issue
NEWSLETTER
In this issue
NOSC on its Way to Grow.31 NOSCs Steering Board Meeting Report.32 NOSCs Recently Published Articles. 34 NOSC Case Study Periodical, Call for Papers.. 35 Neuro-Oncology Events Updates. 36 Featured NOSC Contributors3 7 The International Brain Tumor Awareness Week.. 38 Highlights from ASCO 2013. 39 Neuro-Oncology News Blast41
www.behestandarou.com
31
On the Cover
The most detailed 3D image of the human brain ever taken revealing structures as tiny as 20 microns (50 times smaller than the best MRI technology). The image, made as part of a project called the BigBrain, would serve as a reference point for future studies including the neuro-oncology research. Discovery News 2013-06-21
NOSC NL 2013;2(2)
32
The first NOSCs steering board meeting which was held on 7th March 2013, Tehran, was hosted by the Cancer Society of Iran. Present at the meeting were (alphabetically) : Dr.Amouheidari- Isfahan NOSC lead-faculty; Dr.Fazlalizadeh- Iranian Cancer Society; Dr. Ghadyani- Iranian Cancer Society; Dr.HashemiIranian Radiology Society; Dr. Nayyeri- Iranian Radiology Society; Dr. Nilipour-Iranian Pathology Society; Dr.Samiei- Iranian Society of Radiation Oncology; Dr.Seyednejad- Tabriz NOSC lead-faculty and Dr.TabatabaeefarIranian Society of Radiation Oncology. For informed reasons some invitees including Dr. Ansari- Shiraz NOSC lead-faculty; Dr.AnvariMashhad NOSC lead-faculty; Dr. HaddadIranian Society of Radiation Oncology; Dr.Vosough- Iranian Society of Pediatric Hematology-Oncology; Dr. Zali- National Society of Surgeons (Neurosurgery Branch) and Dr.Zendehdel- National Cancer Research Network, could not attend the meeting.
First, Dr. Fazlalizadeh addressed the meeting with his welcome note. He emphasized that the allied societies taking role in the management of brain tumors should put together patientcentered interests to define shared strategies within NOSC. He further mentioned, when these ideas emerge, we should let them develop as opportunities for the exchange of expertise and optimized practice. These would not only serve the scholars and participants scientific needs but also be expected to improve our patients outcome.
33
Such forums as NOSC can be utilized as a common place for case presentations through which the cross-talk between disciplines can solve many hard-to-tackle issues. Then, Dr.Samiee continued by sharing the positive feeling he had to see experts with brain tumor interest coming from different societies, around a table. He encouraged all societies to support not only NOSC but all similar interdisciplinary communities similarly aiming at oncology patients better life. While recognizing the distinctive role of NOSCs organizing committee under Behestan Darous (BD) support, he recommended that NOSC should be strategically steered by the societies (through their official delegates) in order to continue receiving support and endorsement from the health authorities and policy makers. This will allow NOSC become more authorized and visible in a national scope; he indicated. Later, Dr.Tabatabaeefar refocused on the issue that this club is not intended to belong to a specific group or society. NOSC would remain under the umbrella of all contributing societies as all agreed. Since start, NOSC tried to brand itself as a scientific community disclosing no competing or distinct commercial interest, even though the whole concept was initiated and supported by BD. BD is the main organizer putting together collaborators and members to run NOSC. Moreover, the present steering board is behind all decisions made to let this scientific club pursue its aims. We are here to help this collaborative functional group continue its journey towards optimizing neuro-oncology practice and helping our patients the best we can, he said.
Other contributors such as Dr.Amouheidari and Dr. Hashemi discussed the significance of such activities when related societies equally interact. This will be a major step forward in neuro-oncology practice across Iran, they agreed. Dr.Ghadyani commented on the pivotal role of the steering board and that NOSC can seek registration with the ministry of health as a focus-group and functions independently. Later on, when NOSC becomes a well-established and organized community, societies may take over to further officialize the club. Dr.Samiee, however, was not in agreement and shared his self-experience with the process of officializing such activities. As he indicated, there is no upfront limitations and obstacles to engage societies from the beginning. Most of the participants agreed with the latter ( i.e. top-down) approach. Other delegates including Dr. Nilipour, Dr.Nayeri, Dr.Hashemi and Dr.Seyednejad, commented on the importance of the connect-approach with regard to neuro-oncology applied science and patient care. Documentation of shared updates together with the evidence-based experiences can effectively provide a common pool for all scholars and clinicians in the field to communicate and transfer their expertise in order to find solutions to optimally manage patients. This has been something NOSC tried to render so far. Since NOSCs scientific contributions to the field have strongly been perceived effectual, all participants agreed that parallel to the official process under the societies umbrella, NOSC should continue its scientific activities even stronger than before.
Continued on page.42
NOSC NL 2013;2(2)
34
More recently, we had the other submitted manuscript entitled: Classifying pediatric CNS tumors through near optimal feature selection and mutual information; A single center cohort accepted for publication in the Middle East Journal of Cancer (MEJC). This valuable report which has been contributed by MAHAKs Pediatric Cancer Treatment and Research Center (MPCTRC), is now in press and soon will be published. MEJC is indexed with EMBASE/Excerpta Medica, EBSCO, ISC, CINAHL, DOAJ and Index Copernicus.
35
NOSC NL 2013;2(2)
36
The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology to be held in Conjunction with the 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO). You may want to mark your calendars for the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology to be held November 21-24, 2013, in San Francisco, CA.
37
Continued on page.42
NOSC NL 2013;2(2)
38
To better aware the brain tumor patients of their condition and to provide patient education, NOSC editorial has prepared some fact-sheets in Farsi addressing some of the main questions brain tumor patients have. These fact-sheets are supposed to be widely distributed to brain tumor patients before and during the international brain tumor awareness week .
- Fact Sheet # 1 - Fact Sheet # 2 - Fact Sheet # 3 -Fact Sheet #4 -Fact Sheet #5 - Fact Sheet #6 - Fact Sheet # 7 Brain Tumors Why Me? the Diagnosis Questions to ask your Doctor Telling Family and Friends about your brain tumor Helpful Suggestions What is a Seizure and How Does it Occur Factors Contributing to Behavior and Personality Changes with the Brain Tumor
39
Highlights from
ASCO 13
4 June 2013
The results of two important clinical trials on glioblastoma were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago during 31 May 4 June 2013. The two trials were AVAglio (progressionfree survival and health-related quality of life involving temozolomide and radiotherapy plus bevacizumab in newly-diagnosed GBM, abst# 2023) and RTOG 0825 (a double-blind placebocontrolled trial of bevacizumab in patients with newly-diagnosed GBM). The results created discussion and controversy. Dr. Mark Gilbert, from the MD Anderson Cancer Center, who presented the RTOG 0825 results was reported as stating that in relation to using bevacizumab in newly-diagnosed GBM: Our study would strongly suggest that it is not beneficial to do it as front-line treatment but to reserve it as second-line or salvage therapy. Some commentators worried that the overall results might have an adverse effect on the US Food and Drug Administrations (FDA) sort of conditional approval for bevacizumab and brain tumours in 2009. The worry revolves around the survival advantage as expressed by progressionfree survival (PFS) and overall survival (OS) but Dr. Richard Pazdur from the FDA was reported in the New York Times as stating We have approved a lot of drugs without a survival advantage. Brain tumour patient advocates need to be alert to this ongoing debate about the measurement of the survival advantage of new therapies for brain tumours and express their views when necessary. Meanwhile, in a relatively littlereported media release on 17 June it was stated that bevacizumab had been approved in Japan for newlydiagnosed GBM in combination with TEMOZOLOMIDE plus RADIOTHERAPY and as monotherpy for recurrent GBM. The approval was based on the Phase II BRAIN study, a Japanese Phase II study (JO22506) and the Phase III AVAglio study. Furthermore, it was stated that applications for first-line treatment have been filed in the European Union and Switzerland. However , the FDA has not yet approved this combination and according to the so far established protocols, the standard-of -care for GBM remains six weeks concomitant temozolomide and radiotherapy followed by adjuvant temozolomide. Source: http://chicago2013.asco.org/
NOSC NL 2013;2(2)
40
The Stupp regimen preceded by early post-surgery temozolomide versus the Stupp regimen alone in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM).
J Clin Oncol 31, 2013 (suppl; abstr 2022)
ASCO
13
Background: In treatment of newly diagnosed GBM with the Stupp chemo-radiotherapy regimen, following by adjuvant chemotherapy, patients were treated with temozolomide (TMZ) & combined radiotherapy 4-5 weeks after surgery. In the interval between surgery and chemo-radiotherapy, it is not known whether additional TMZ treatment will improve efficacy or safety. This trial evaluated the safety and efficacy of the Stupp regimen + early post-surgery TMZ chemotherapy in the treatment of patients with newly diagnosed GBM. Methods: The trial was a multi-center, randomized open-label study. 99 newly diagnosed GBM patients were enrolled and randomly assigned to the Stupp regimen + early postsurgery TMZ chemotherapy arm (experimental group, n = 52) or to Stupp regimen alone (control group, n = 47). Fourteen days after surgery, the patients in experiment group recieved TMZ orally at 75mg/m2/day for 14 days. The primary endpoint of the study was the overall survival (OS). The secondary endpoints included the progression-free survival (PFS), objective tumor assessment and adverse events (AEs). Results: The median OS time was 17.58 months (95% CI: 15.18 23.03 months) in the experiment group and 13.17 months (95% CI: 11.14 18.76 months) in the control group (logrank test, p = 0.021). There is no significantly difference in the median PFS between experiment group and control group (8.74 months, 95% CI: 6.41-14.85 months vs 10.38 months, 95% CI: 8.18-15.44 months, p = 0.695). No statistically significant difference was detected as regards to the objective tumor assessments. There is no significance in OS or PFS between MGMT positive and MGMT negative groups. TMZ treatment was well tolerated in the study. AE types and rates were generally similar between the two groups. There were 22 SAEs in this study, with only 1 SAE (lung infection) in Stupp regimen group was possibly drug-related. Conclusions: The addition of early post-surgery TMZ chemotherapy to the Stupp regimen for newly diagnosed GBM resulted in a statistically significant survival benefit with minimal additional toxicity. Clinical trial information: NCT00686725.
NOSC NL 2013;2(2)
41
42
The rationale for the continuation of NOSCs scientific patient-oriented activities was agreed upon during this meeting. Everybody was in line with the pre-specified mission and vision of this scientific club. Attendees agreed that further steering board meetings should be conducted during which many detailed questions will be addressed. Exploring some central questions such as : Radio-diagnostic advances in CNS tumors; how this can optimize care?; Safe maximal resection of brain tumors and functional surgery set up; where? when? how?; Brain tumor tissue bank, ifs and buts!; Brain tumor collaborative registry (BTCR), how to make it a real success?; Priorities in forth coming provincial NOSC meetings?; Co-chair panel and speakers for the following NOSC sessions?; Newsletter, comments? NOSC case study periodical, how to boost contributions? NOSC membership?; International collaborations (International members/patrons?); International speakers board?; NOSC member, faculty and lead-faculty definition?; Brain tumor joint seminars (problem case discussions)? Where/when to hold such a thing? would line up NOSCs future strategies even clearer, and are expected to be the main constituent of the future steering board meetings. Cancer society has graciously accepted to host this session and even further gatherings while re-emphasized that NOSC belongs to all contributing societies. Participants were delighted for this invitation and agreed to expect invitation to the following NOSC steering board meeting issued by the cancer society of Iran aiming to catalyze the steering boards planned activities. NOSC is to receive support from national scientific societies contributing to such a viable field; the Neuro-Oncology.
Disclosure: Conduction of the NOSCs steering board meeting was made possible through logistic supports from Behestan Darou PJS.
In collaboration with the NOSC lead-faculty members in Mashhad, Dr. Anvari has notably contributed to the so far conducted NOSC activities there. He has been a member of the NOSC founding panel and the moderator of the so far conducted scientific activities. He also functions as a member of NOSC steering committee across the country. Since last year, Dr. Anvari has invited distinguished oncologists - pathologist immunologist and geneticist to form a CNS tumor study group in Mashhad. This study group has been working on defined brain tumor research projects in collaboration with the Oncology Research Center and related authorities in Mashhad University of Medical Sciences.
NOSC receives scientific support from the Medical Division of Behestan Darou PJS.
www.behestandarou.com